MUMBAI, Dec 24 (Reuters) - India's Dr. Reddy's Laboratories Ltd (REDY.BO: Quote, Profile, Research, Stock Buzz)(RDY.N: Quote, Profile, Research, Stock Buzz) has received tentative approval from the U.S. Food and Drug Administration for heartburn drug pantoprazole sodium in the extended release tablet format, the regulator's Web site showed. (Reporting by Rina Chandran; Editing by John Mair)
© Thomson Reuters 2008 All rights reserved
A selection of our best photos from the past 24 hours. View Slideshow
Reuters.com:
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Interactive TV |
Labs |
Reuters in Second Life |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cash injection
Panic grips Asian investors